Bifogade filer
Interim Report Q3 2023 MagleGroup
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Magle Chemoswed via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2023-10-25 08:30:00
Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.
Q3 2023 KEY INDICATORS
- Net sales amounted to 36.3 MSEK (34.1)
- EBITDA equalled 4.8 MSEK (4.8)
- Operating profit (EBIT) is 1.5 MSEK (1.4)
- Profit after tax amounted to 0.5 MSEK (1.2)
- Earnings per share SEK 0,1 (0,1) per share
JAN-SEPT 2023 KEY INDICATORS
- Net sales amounted to 113.1 MSEK (99.8)
- EBITDA equalled 21.8 MSEK (20.1)
- Operating profit (EBIT) is 12.1 MSEK (10.1)
- Profit after tax amounted to 8.1 MSEK (9.1)
- Earnings per share SEK 0,8 (0,8) per share
“Magle Group has made yet another strong quarter, both in terms of revenue and profit. Total revenues from our CDMO business and DSM-based products increased by 6.7% percent compared to last year’s corresponding period, which is well within our expectations. During the quarter, we have taken a major step in our commercialization strategy by signing a worldwide distribution agreement with the global medical device company, Sirtex Medical” says Justin Pierce, CEO
The full report is available at https://maglegroup.com/financial-reports/